New Data on Ocrelizumab
Researchers will be presenting, at the upcoming American Academy of Neurology (AAN) meeting beginning on April 21st, 2018, new data on the use of ocrelizumab (OCREVUS; Genentech, San Francisco, CA), which is approved for treating adults with relapsing or primary progressive forms of multiple sclerosis. The data reinforces the efficacy and safety of ocrelizumab. Of note, is the early impact of ocrelizumab on biomarkers of inflammation and neurodegeneration in patients with relapsing multiple sclerosis (RMS). Other presentations highlight the benefit of the drug in slowing disability progression and benefits in cognition.
The FLOODLIGHT pilot study, which supports mobile technology as a complement to in-clinic testing is providing more complete and real-time understanding of patients’ disease activity, that will be presented.
Visit us at www.practicalneurology.com to see more news of these and other results from the AAN meeting!